12X1 Stock Overview
A clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Anavex Life Sciences Corp. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$8.54 |
| 52 Week High | US$9.32 |
| 52 Week Low | US$3.05 |
| Beta | 0.60 |
| 11 Month Change | 77.89% |
| 3 Month Change | 54.45% |
| 1 Year Change | 37.45% |
| 33 Year Change | -49.74% |
| 5 Year Change | 306.86% |
| Change since IPO | -24.36% |
Recent News & Updates
Recent updates
Shareholder Returns
| 12X1 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 20.8% | -0.7% | -0.02% |
| 1Y | 37.5% | -17.2% | 8.2% |
Return vs Industry: 12X1 exceeded the German Biotechs industry which returned -17.2% over the past year.
Return vs Market: 12X1 exceeded the German Market which returned 8.2% over the past year.
Price Volatility
| 12X1 volatility | |
|---|---|
| 12X1 Average Weekly Movement | 13.1% |
| Biotechs Industry Average Movement | 6.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.3% |
Stable Share Price: 12X1's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 12X1's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 40 | Chris Missling | www.anavex.com |
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer’s disease and Parkinson’s disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company’s drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer’s disease.
Anavex Life Sciences Corp. Fundamentals Summary
| 12X1 fundamental statistics | |
|---|---|
| Market cap | €741.82m |
| Earnings (TTM) | -€39.88m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-18.6x
P/E RatioIs 12X1 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 12X1 income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$41.53m |
| Earnings | -US$41.53m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.49 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did 12X1 perform over the long term?
See historical performance and comparison